Circassia Pharmaceuticals PLC (LON:CIR) has earned a consensus rating of “Buy” from the six brokerages that are covering the firm. Three analysts have rated the stock with a hold recommendation and three have assigned a buy recommendation to the company. The average 1 year price target among analysts that have issued ratings on the stock in the last year is GBX 145 ($1.81).

A number of equities analysts have commented on CIR shares. Peel Hunt reaffirmed an “add” rating and issued a GBX 160 ($2.00) price objective on shares of Circassia Pharmaceuticals PLC in a report on Tuesday, September 27th. Numis Securities Ltd reaffirmed a “buy” rating and issued a GBX 150 ($1.87) price objective on shares of Circassia Pharmaceuticals PLC in a report on Tuesday, September 27th. Finally, JPMorgan Chase & Co. decreased their price objective on shares of Circassia Pharmaceuticals PLC from GBX 170 ($2.12) to GBX 140 ($1.75) and set an “overweight” rating for the company in a report on Wednesday, September 28th.

Circassia Pharmaceuticals PLC (LON:CIR) opened at 82.50 on Wednesday. The stock’s market cap is GBX 235.03 million. Circassia Pharmaceuticals PLC has a one year low of GBX 78.45 and a one year high of GBX 322.90. The stock has a 50 day moving average of GBX 88.49 and a 200-day moving average of GBX 134.71.

Circassia Pharmaceuticals PLC Company Profile

Circassia Pharmaceuticals plc is a specialty biopharmaceutical company focused on allergy and respiratory diseases. The Company operates through three segments: Allergy, which relates to a range of immunotherapy development products for the treatment of allergy; NIOX, which relates to the portfolio of products used to improve asthma diagnosis and management by measuring fractional exhaled nitric oxide (FeNO), and Respiratory, which relates to the portfolio of asthma and chronic obstructive pulmonary disease product candidates.

Receive News & Stock Ratings for Circassia Pharmaceuticals PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Circassia Pharmaceuticals PLC and related stocks with our FREE daily email newsletter.